Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of nemolizumab in adults with systemic sclerosis
CTR20263715Phase 2Active
- Sponsor
- Galderma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nemolizumab in systemic sclerosis (SSc), sponsored by Galderma. Started Sep 2026; status: active.
02
Drugs
nemolizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20263715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263715.